Navigation Links
Lung cancers detected by CT screening grow as fast as those found with traditional methods
Date:3/30/2012

A new study led by researchers at Mount Sinai School of Medicine indicates that CT scans are more effective than traditional lung cancer detection methods at identifying aggressive lung cancers in their most treatable stages. The data, published online March 27 in the journal Radiology, demonstrate that lung cancers found through annual CT screening are similar to those found in routine practice, both in terms of tumor growth rates and cell-type distribution. In fact, the report showed that 79 percent of the cases diagnosed through annual repeat CT scans were detected at clinical Stage I, the earliest and most treatable stage, compared to only 15 percent detected through traditional methods.

The study, which is the latest report from the International Early Lung Cancer Action Program (I-ELCAP), counters concerns that lung cancers diagnosed through annual repeat rounds of computed tomography (CT) screening may be of less serious varieties than those diagnosed in traditional clinical settings when symptoms are already present.

"We've previously shown that, similar to common screening methods such as mammography for breast cancer, annual CT scans are effective in early detection of lung cancer. However, there were concerns that the cancer found in these screenings were less serious than those found in routine practice in the clinical setting, and often resulted in excessive treatment," said Claudia I. Henschke, PhD, MD, Professor of Radiology at Mount Sinai School of Medicine and I-ELCAP principal investigator. "However, the data show that lung cancers detected with annual repeat rounds of CT scans are just as lethal and require equally aggressive treatment."

I-ELCAP is an international collaborative group of more than 60 participating institutes consisting of experts on lung cancer related diseases. Previous research from the group found that lung cancers detected through CT screening have an 80 percent cure rate compared to a 10 percent cure rate for lung cancers detected in the clinical setting.

"Lung cancer is by far the leading cause of cancer death among both men and women. However, when lung cancer is caught in an early, treatable stage, the cure rates are significantly higher," said Dr. Henschke. "It is recommended that people at high risk for lung cancer speak with their health care provider to discuss the benefits and risks of screening in order to make an informed decision about enrolling in a screening program."

Lung cancer accounts for more annual deaths than colon, breast, and prostate cancers combined. The American Cancer Society estimates that in 2012, approximately 226,160 new cases of lung cancer will be diagnosed in the United States and 160,340 Americans will die from the disease.

For this study, the researchers reviewed pooled results from the I-ELCAP database for 1993 to 2009, consisting of men and women at risk for lung cancer who underwent annual repeat rounds of CT screening. Researchers found 111 cases of lung cancer, 90 of which were non-small-cell cancers. Out of the 111 cases, 79 percent were clinical Stage I, the earliest and most treatable stage. Non-small-cell lung cancer is the most common form of lung cancer.

The researchers then compared their findings to a 2008 study published in the Journal of Thoracic Oncology analyzing the growth rates of non-small-cell lung cancers detected through traditional methods. The 2008 study found that only about 15 percent of those cancers were discovered in Stage I.

The researchers also found that while the first round of CT screening detected a higher proportion of slower-growing cancers than those detected in clinical practice, the subsequent annual repeat rounds of screening reflected what is found in clinical practice.

The investigators then analyzed volume doubling time or growth rate and cell-type distribution of the cancers. The mean volume doubling time for all cases was 136 days. Volume doubling times for lung cancers diagnosed in clinical practice ranged from 20 to 360 days. For the 90 non-small-cell cancers, mean volume doubling time was 154 days compared to 135 days in the 2008 study.

When researchers evaluated the cell-types of the cancers, they found the frequencies of small-cell carcinoma, which usually develops in the central areas of the lung, and adenocarcinoma, usually located on the outer surface of the lungs, to be approximately 19 percent and 50 percent, respectively. In the 2008 study these frequencies were nearly identical, at 20 percent and 50 percent.

In addition, the researchers found that 89 percent of the cancers that manifested as solid nodules had significantly faster volume doubling times than the sub-solid nodule cancers and may need a less aggressive diagnosis and treatment approach. The researchers defined cancerous nodules as solid if they obscured all of the lung tissue and sub-solid if they did not.

"Identifying the varying growth rates for specific lesion types should allow us to create a more tailored treatment for the patient," said Dr. Henschke.


'/>"/>

Contact: Mount Sinai Medical Center Press Office
NewsMedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
2. Researchers chart genomic map spanning over 2 dozen cancers
3. Scientists Spot Genetic Fingerprints of Individual Cancers
4. Accelerated radiation therapy reduces toxicity in patients with advanced head and neck cancers
5. Proton beam therapy shows encouraging long-term outcome for patients with locally advanced sinonasal cancers
6. Herceptin and Tykerb effective against a subset of gastric cancers
7. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
8. Exploiting the architecture of cancers may lead to their destruction
9. Palpable breast cancers are more common in women not undergoing annual mammography
10. Non-Melanoma Skin Cancers in the Millions and Rising
11. Virtual colonoscopy allows detection of unsuspected cancers beyond colon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ChenMed, a privately ... completion of the strategic executive team expansion needed to further optimize growth and ... executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. “George Wheeler ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... It’s that ... means many students are thinking about summer internships , which can be frustrating ... , The pros at Garden Media Group, a boutique public relations firm outside of ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Leaders Engaged ... and fatal diseases in opposition to the President’s Fiscal Year 2018 Federal ... services, and hope for the most vulnerable among us. , The proposed budget ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Boulevard is honored to ... All events will be located in the Main West Entrance of The Boulevard ... ID event. No appointment is necessary and each child with a parent or guardian ...
(Date:3/23/2017)... ... , ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: a call to ... the creation of published author, Desiree M Webb, a registered nurse, minister of music, ... happily married to her husband, Paul, for over twenty-nine years. Desiree enjoys writing, ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017 The Board of Directors of ... General Meeting, which is to take place on Thursday, April 27, ... Lund, Sweden . ... Please see the attached notification, which is being announced ... NeuroVive Pharmaceutical AB (Publ) The Board Of Directors ...
(Date:3/22/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Respiratory care devices ... over the next decade to reach approximately $38.27 billion by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... , March 22, 2017 Ampio ... the development of Ampion™, a low molecular weight ... today announced that it is re-issuing its previous release ... incorporate certain disclosures that are required under the ... below are these additional disclosures along with the ...
Breaking Medicine Technology: